Clinical trials: NYHA Class III Heart Failure
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Heart failure (HF) is a major healthcare problem. In patients with Heart Failure with Reduced Ejection Fraction (HFrEF), aldosterone antagonists reduce mortality and hospitalization rate.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- GBDAL-HF (NCT06233695)
- Testing
- Potassium sparing diuretic
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
NYHA Class III Heart Failure
Correlation of SOZO BIS Measures With CardioMEMS PA Pressure
This study aims to establish the degree to which change in the ratio of ECF to TBW measured using the SOZO BIS device correlates with change in end-expiratory end-diastolic PAP measured using the CardioMEMS HF System (St.
- Trial name
- NCT02939053
- Testing
- SOZO
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- ImpediMed Limited
Congestive Heart Failure
A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure
This is a Phase 1, single-center, randomized, double-blind, single ascending dose, placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart failure due to left ventricular systolic dysfunction, to…
- Trial name
- NCT02388464
- Testing
- MTP-131
- Where
- Bulgaria
- Volunteers
- 36 people
- Sponsor
- Stealth BioTherapeutics Inc.
Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II
Yoga Based Cardiac Rehabilitation in Heart Failure Failure
The clinical study compares the benefits of yoga based rehabilitation programme versus an educational package during recovery of patients with heart failure.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- Yoga-CaRe HF (NCT07817589)
- Testing
- Yoga-CaRe HF, Health Education
- Where
- 16 sites in India
- Volunteers
- 3,500 people
- Sponsor
- Centre for Chronic Disease Control, India
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Whole Heart Radiotherapy for End-stage Heart Failure
End-stage heart failure (ESHF) causes recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard HF therapies are common as the disease progresses.
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV, End-stage Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- ESHF-WHRT (NCT06299176)
- Testing
- Whole Heart Radiation Therapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Heart Failure NYHA Class III
SIRONA 2 Trial Heart Failure NYHA Class III
This is a prospective, multi-center, open-label, single-arm CE-Mark trial to assess device safety and efficacy of the Cordella PA Sensor System in up to 75 New York Heart Association (NYHA) Class III Heart Failure patients who…
- Trial name
- NCT04012944
- Testing
- Cordella™ Pulmonary Artery Sensor System
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 81 people
- Sponsor
- Endotronix, Inc.
Heart Failure
Warfarin and Antiplatelet Therapy in Chronic Heart Failure
Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics.
- Trial name
- NCT00007683
- Testing
- Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
- Where
- 134 sites in United States, Canada and 1 more
- Volunteers
- 1,587 people
- Sponsor
- US Department of Veterans Affairs
Heart Failure, Congestive
Study of DITPA in Patients With Congestive Heart Failure
This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3.
- Trial name
- NCT00103519
- Testing
- DITPA (3,5-diiodothyropropionic acid)
- Where
- 22 sites in United States
- Volunteers
- 86 people
- Sponsor
- Titan Pharmaceuticals
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Family Palliative and End-of-Life Care for Advanced Heart Failure
Overall objective is to test whether the 5-weekly family home palliative and end-of-life care (FamPALcare) intervention educational and supportive sessions will improve rural home end-of-life and palliative care (EOLPC) for…
- Trial name
- NCT04153890
- Testing
- FamPALcare
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- West Virginia University
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure NYHA Class III
HEart fAiluRe evaluaTion Questionnaire
The "four-point" questionnaire by Severo and his associates was weighted in 2011 in the Portuguese population and aims to characterize the severity of the symptoms of heart failure by providing a way to minimize the reliability…
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure NYHA Class II, Heart Failure NYHA Class I
- Trial name
- HEART (NCT03895073)
- Testing
- healthy volunteers
- Where
- Greece
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- John Parissis
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone
Aldosterone antagonists or mineralocorticoid receptor antagonists (MRAs) are used as therapeutic agents for the management of HF with reduced ejection fraction (HFrEF).
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT06641284
- Testing
- Spironolactone
- Where
- Saudi Arabia
- Volunteers
- 509 people
- Sponsor
- Ahmad Abdullah Salawi
Heart Failure, Congestive
ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure
The main purpose of this study is to see if the experimental drug ZP120, when given with the approved drug furosemide to patients with acute or sub-acute heart failure, can reduce the amount of fluid in the patients' lungs and…
- Trial name
- NCT00283361
- Testing
- ZP120, I.v. catherization, 6-minutes walk performance
- Where
- 22 sites in United States
- Volunteers
- 130 people
- Sponsor
- Zealand Pharma
Congestive Heart Failure
Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.
The purpose of this study is to determine the effect of two different doses of MCC-135, once daily (QD) or twice daily (BID), on the disease state and the quality of life in subjects with congestive heart failure.
- Trial name
- NCT00050076
- Testing
- MCC-135
- Where
- 53 sites in United States
- Volunteers
- 204 people
- Sponsor
- Takeda
Heart Failure
Effects of Triiodothyronine (T3) in Ischemic Heart Failure
This study aims to determine whether giving triiodothyronine (T3), a thyroid hormone, is safe and helps improve symptoms and signs of heart failure.
- Trial name
- NCT05384847
- Testing
- Thyroid hormone T3, Control Group
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Heart Failure, Heart Failure, Systolic
Hemodynamic-GUIDEd Management of Heart Failure
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II
- Trial name
- GUIDE-HF (NCT03387813)
- Testing
- CardioMEMS™ HF System
- Where
- 129 sites in United States, Canada
- Volunteers
- 2,358 people
- Sponsor
- Abbott Medical Devices
Decompensated Chronic Heart Failure, Heart Failure NYHA Class III
Epidemiology and Prognostic of the Acute Heart Failure
EPICAL 2 (Epidemiology and prognostic of the Acute Heart Failure) is an epidemiological, observational, prospective and multicenter study.
- Conditions
- Decompensated Chronic Heart Failure, Heart Failure NYHA Class III, Acute Pulmonary Edema, Cardiogenic Shock
- Trial name
- EPICAL2 (NCT02880358)
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Central Hospital, Nancy, France
Chronic Heart Failure
Evaluation of Longterm Outcome of New York Heart Association Class III Heart Failure Patients Receiving Telemonitoring Using a Pulmonary Artery Pressure Sensor System (CardioMEMS)
Invasive hemodynamic monitoring in advanced heart failure patients is a relative new option. In order to investigate the impact of remote telemonitoring of pulmonary artery pressures on mortality and morbidity in a routine…
- Trial name
- NCT03020043
- Where
- 2 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Congestive Heart Failure(CHF)
Ketone and Hawthorn Extract Supplementation in Congestive Heart Failure
The purpose of this research is to gain a better understanding of whether supplements can improve heart health. There are a number of study procedures and tests that will occur as a part of the research study.
- Trial name
- NCT07166965
- Testing
- Hawthorn supplement, Ketones
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Jefferson University
Heart Failure
Cardiac Rehab for Advanced Heart Failure-LVAD Candidates
This study is a pilot study evaluating the feasibility and early efficacy of cardiac rehabilitation to improve frailty and symptoms in patients with advanced heart failure (NYHA class III-IV), who are being considered for LVAD…
- Trial name
- NCT03132441
- Testing
- Strength Training for Frailty
- Where
- United States
- Sponsor
- Mayo Clinic